PRANAZEPIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H19FN4O2
Molecular Weight	438.4531
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC1=C(C=CC=C1)C2=N[C@H](NC(=O)C3=CC4=C(N3)C=CC=C4)C(=O)N5CCC6=C5C2=CC=C6

InChI

InChIKey=WKJDXKWFGJWGAS-XMMPIXPASA-N

InChI=1S/C26H19FN4O2/c27-19-10-3-2-8-17(19)22-18-9-5-7-15-12-13-31(23(15)18)26(33)24(29-22)30-25(32)21-14-16-6-1-4-11-20(16)28-21/h1-11,14,24,28H,12-13H2,(H,30,32)/t24-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C26H19FN4O2
Molecular Weight	438.4531
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://adisinsight.springer.com/drugs/800003071https://www.ncbi.nlm.nih.gov/pubmed/7805132
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8680546

(R)-FK480 is enantiomer of a cholecystokin-type-A (CCK-A) receptor antagonist FK480. Binding of (R)-FK480 to CCK-A is 26 times less potent than (S)-FK480.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cholecystokinin A receptor 7 Target ID: CHEMBL1901 Sources: http://adisinsight.springer.com/drugs/800003071 \| https://www.ncbi.nlm.nih.gov/pubmed/7805132	Antagonist 2849		0.4 nM [IC50]
Cholecystokinin A receptor 7 Target ID: CHEMBL1901 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7805132	Binding Agent 1076		18.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pancreatitis 16 Sources: http://adisinsight.springer.com/drugs/800003071	Primary		Phase II 1147	Unknown Approved Use Unknown
Unknown 2596

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.005% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11560875/			PRANAZEPIDE plasma	Homo sapiens

PubMed

Title	Date	PubMed
Studies on a novel, potent and orally effective cholecystokinin A antagonist, FK-480. Synthesis and structure-activity relationships of FK-480 and related compounds.	1994-10	7805132
Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.	1994-02	7509389

Patents

Sample Use Guides

In Vivo Use Guide

Rats: FK480 (PRANAZEPIDE) inhibited pancreatic exocrine secretion dose dependently at doses of 0.01-1.0 mg/kg.

Route of Administration: Oral

In Vitro Use Guide

PRANAZEPIDE (10 nM) blocked calcium oscillation induced by CCK (10 pM) in isolated rat pancreatic acini..

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:24:38 GMT 2025` Edited by `admin` on `Mon Mar 31 21:24:38 GMT 2025`
Record UNII	10TO0RP68C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PANAZEPIDE

Preferred Name

English

PRANAZEPIDE

Official Name

English

pranazepide [INN]

Common Name

English

PANAZEPIDE [JAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C547